Surgical Science has carried out a primary issuance of shares of approximately SEK 2.7 billion at a subscription price of SEK 210 per share. The subscription price was determined through an accelerated bookbuilding procedure.
Surgical Science is a world leader in the manufacture of virtual reality simulators for evidence-based laparoscopic and endoscopic training. The simulators enable surgeons and other medical specialists to train and improve their psychomotor skills and instrument handling before entering the operating room. In parallel with its own products, Surgical Science works with simulation solutions for medical technology companies that develop surgical instruments for clinical use, such as robotic surgery.
The share issue was carried primarily be used to finance the acquisition of Simbionix USA Corp.
Pareto Securities acted as Sole Manager and Bookrunner. Baker McKenzie acted as legal advisor to Pareto Securities. Joakim Falkner, Johanna Flink and Carl Isaksson from Baker McKenzie's Capital Markets team in Stockholm were involved in the transaction, as well as Adam Farlow and Charles Farnsworth from the Capital Markets team in London.